We are live on !
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$335M
Turnover
79.96%
1-Year Est. Return
275.57%
This Fund
S&P 500
This Quarter Est. Return
+61.37%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$66.9M
(+25%)
Cap. Flow
-$37.3M
Cap. Flow % of AUM
Cap. Flow %
-11.13%
Top 10 Holdings %
Top 10 Hldgs %
34.76%
Holding
938
New
616
Increased
74
Reduced
90
Closed
134
Avg Time Held
Equity + Options
0.1
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Robinhood
HOOD
|
+$16M |
| 2 |
STMicroelectronics
STM
|
+$13.6M |
| 3 |
Amphenol
APH
|
+$10.9M |
| 4 |
Seagate
STX
|
+$7.07M |
| 5 |
Ford
F
|
+$6.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sandisk
SNDK
|
+$18.4M |
| 2 |
Lumentum
LITE
|
+$14.5M |
| 3 |
AXT Inc
AXTI
|
+$13.3M |
| 4 |
Tower Semiconductor
TSEM
|
+$11.9M |
| 5 |
Micron Technology
MU
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.35% |
| 2 | Healthcare | 29.66% |
| 3 | Financials | 6.33% |
| 4 | Miscellaneous | 6.14% |
| 5 | Consumer Discretionary | 5.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
CRH
CRH
$55.2B
| $822K | 0.25% |
7,678
-3,565
| -32% | -$392K |
2026 Q1
1 quarter
|
|
77
Qnity Electronics Inc
Q
$24.9B
| $791K | 0.24% |
4,844
-270
| -5% | -$39.8K |
2026 Q1
1 quarter
|
|
78
Inventiva
IVA
$704M
| $791K | 0.24% |
209,182
+81,083
| +63% | +$390K |
2025 Q4
2 quarters
|
|
79
B2Gold
BTG
$6.92B
| $781K | 0.23% |
+208,812
| New | +$958K |
2026 Q2
0 quarters
|
|
80
Spyre Therapeutics
SYRE
$7.89B
| $778K | 0.23% |
8,760
+3,957
| +82% | +$289K |
2025 Q4
2 quarters
|
|
81
Dorian LPG
LPG
$2.24B
| $774K | 0.23% |
+21,951
| New | +$864K |
2026 Q2
0 quarters
|
|
82
AstraZeneca
AZN
$255B
| $769K | 0.23% |
4,058
+2,822
| +228% | +$531K |
2026 Q1
1 quarter
|
|
83
Nurix Therapeutics
NRIX
$2.74B
| $751K | 0.22% |
+30,973
| New | +$528K |
2026 Q2
0 quarters
|
|
84
Corbus Pharmaceuticals
CRBP
$85.3M
| $722K | 0.22% |
76,919
-34,307
| -31% | -$325K |
2025 Q4
2 quarters
|
|
85
Marvell Technology
MRVL
$214B
| $721K | 0.22% |
2,421
-12,261
| -84% | -$2.46M |
2026 Q1
1 quarter
|
|
86
Vera Therapeutics
VERA
$2.07B
| $707K | 0.21% |
+16,485
| New | +$614K |
2026 Q2
0 quarters
|
|
87
First Solar
FSLR
$18.4B
| $702K | 0.21% |
3,013
-163
| -5% | -$38.2K |
2025 Q3
3 quarters
|
|
88
CALL
Capricor Therapeutics
CAPR
$383M
| $697K | 0.21% |
831
| – | – |
2025 Q3
3 quarters
|
|
89
Oruka Therapeutics
ORKA
$4.98B
| $674K | 0.2% |
+7,085
| New | +$472K |
2026 Q2
0 quarters
|
|
90
Definium Therapeutics
DFTX
$4.44B
| $648K | 0.19% |
13,778
-2,083
| -13% | -$51.5K |
2026 Q1
1 quarter
|
|
91
Guardant Health
GH
$21.4B
| $641K | 0.19% |
4,275
+189
| +5% | +$20.6K |
2026 Q1
1 quarter
|
|
92
Darling Ingredients
DAR
$9.48B
| $633K | 0.19% |
11,901
+2,243
| +23% | +$134K |
2025 Q4
2 quarters
|
|
93
PBF Energy
PBF
$9.5B
| $632K | 0.19% |
13,606
+7,188
| +112% | +$299K |
2026 Q1
1 quarter
|
|
94
Sanofi
SNY
$95.2B
| $629K | 0.19% |
14,750
+4,804
| +48% | +$215K |
2025 Q4
2 quarters
|
|
95
Bloom Energy
BE
$66.4B
| $622K | 0.19% |
2,054
+1,809
| +738% | +$463K |
2025 Q3
3 quarters
|
|
96
Thermo Fisher Scientific
TMO
$252B
| $619K | 0.18% |
1,235
+732
| +146% | +$351K |
2025 Q4
2 quarters
|
|
97
Stryker
SYK
$115B
| $604K | 0.18% |
1,918
+808
| +73% | +$255K |
2025 Q4
2 quarters
|
|
98
Relmada Therapeutics
RLMD
$336M
| $598K | 0.18% |
86,443
+35,670
| +70% | +$249K |
2025 Q4
2 quarters
|
|
99
UnitedHealth
UNH
$364B
| $593K | 0.18% |
+1,427
| New | +$529K |
2026 Q2
0 quarters
|
|
100
GeneDx Holdings
WGS
$1.93B
| $587K | 0.18% |
+8,555
| New | +$486K |
2026 Q2
0 quarters
|
|
Similar funds
JWM
PI
TFA
SIM
OWM
SS
BIA
TODC
Persistent Asset Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Persistent Asset Partners held 938 positions worth $335M, up 25% from $268M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Persistent Asset Partners withdrew a net $37.3M in Q2 2026, closing 134 positions and reducing 90 holdings. Its most notable exit was Lumentum, an estimated $14.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Persistent Asset Partners opened a new position in Robinhood worth $19.2M.
- Persistent Asset Partners's largest Q2 2026 buy was Robinhood: 191,095 shares worth $19.2M.
- Persistent Asset Partners added most to United Therapeutics in Q2 2026, an estimated $3.99M increase.
- Persistent Asset Partners's biggest Q2 2026 reduction was Sandisk, cutting an estimated $18.4M.
- Persistent Asset Partners fully exited Lumentum in Q2 2026, selling an estimated $14.5M.
- Persistent Asset Partners's ten largest holdings make up 35% of its $335M portfolio in Q2 2026.
- Persistent Asset Partners opened 616 new positions and closed 134 in Q2 2026.
- Persistent Asset Partners's portfolio value rose 25% quarter-over-quarter to $335M.
Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.